Human Immunoglobulin E specific for Equus caballus dander allergens (Horse-specific IgE) (Horse-specific IgE)

Human Immunoglobulin E (IgE) antibodies specific for Equus caballus dander allergens are specialized proteins produced by the immune system in response to exposure to horse-derived proteins, primarily lipocalins like Equ f 1 and Equ f 2 (PMID: 11856415). These antibodies play a central role in Type I hypersensitivity reactions by binding to high-affinity FcεRI receptors on the surface of mast cells and basophils (PMID: 12487214). When a sensitized individual is re-exposed to horse dander, the allergens cross-link the IgE molecules, triggering the immediate release of inflammatory mediators like histamine, prostaglandins, and leukotrienes. This physiological response results in clinical manifestations such as allergic rhinitis, conjunctivitis, and potentially life-threatening asthma or anaphylaxis (PMID: 15985811). Therapeutic interventions, such as the monoclonal antibody omalizumab, target the circulating IgE to prevent its binding to receptors, effectively reducing the allergic inflammatory cascade (PMID: 24565772). Additionally, allergen-specific immunotherapy (AIT) aims to modulate the immune response to these specific antibodies by inducing desensitization and immune tolerance.

Other names

Horse dander-specific IgEAnti-Equus caballus IgEEqu f 1-specific IgEEqu f 2-specific IgEEqu f 3-specific IgEEqu f 4-specific IgEEqu f 5-specific IgEEqu f 6-specific IgE

Binding to the Fc region of circulating IgE to prevent its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils, thereby inhibiting the release of inflammatory mediators (PMID: 12487214).